Matthew R. Kwietniak
2023
Compensation breakdown
| Non-Equity Incentive Plan | $146,700 |
|---|---|
| Salary | $360,154 |
| Stock Awards | $730,298 |
| Other | $46,732 |
| Total | $1,283,884 |
Kwietniak received $730.3K in stock awards, accounting for 57% of the total pay in 2023.
Kwietniak also received $146.7K in non-equity incentive plan, $360.2K in salary and $46.7K in other compensation.
Rankings
In 2023, Matthew R. Kwietniak's compensation ranked 933rd out of 2,918 executives tracked by ExecPay. In other words, Kwietniak earned more than 68.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 933 out of 2,918 | 68th |
Division Manufacturing | 557 out of 1,608 | 65th |
Major group Chemicals And Allied Products | 379 out of 901 | 58th |
Industry group Drugs | 368 out of 864 | 57th |
Industry Pharmaceutical Preparations | 249 out of 622 | 60th |
Pay ratio
| Matthew R. Kwietniak's Pay | $1,283,884 |
|---|---|
| Median Employee's Pay | $104,595 |
| Pay Ratio | 12to 1 |
In 2023, the annual total compensation of Matthew R. Kwietniak was $1,283,884.
The annual total compensation of the median employee at Peregrine Pharmaceuticals was $104,595.
The ratio of Matthew R. Kwietniak's pay to the pay of median employee was therefore 12 to one.
Kwietniak's colleagues
We found four more compensation records of executives who worked with Matthew R. Kwietniak at Peregrine Pharmaceuticals in 2023.